VGLL4 enhances PDK4 transcription and promotes metabolic dysfunction-associated fatty liver disease
The VGLL4–TEAD4/CEBPA–PDK4 axis as a key driver of MAFLD is unveiled and its pharmacological blockade alleviates hepatic steatosis in model mice and represents a viable strategy to halt MAFLD progression.